TORONTO–(BUSINESS WIRE)–The Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit organization dedicated to advancing health technology innovation and commercialization, is proud to announce the launch of the first eight Early A …
TORONTO–(BUSINESS WIRE)–The Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit organization dedicated to advancing health technology innovation and commercialization, is proud to announce the launch of the first eight Early Adopter Health Network (EAHN™) innovation projects.
EAHN is driving innovation in the Canadian health science industry into the Ontario health system through an end-to-end process, extending from technology evaluation to commercialization.
Since the EAHN call for applications on May 14, OBIO has evaluated over 70 applications from across Canada and selected the most commercial-ready technologies. Utilizing industry-driven expertise in assessing health technologies, OBIO has partnered each of these eight leading-edge technologies with Ontario health care organizations to complete rapid evaluations.
“OBIO’s EAHN gives Canadian health technology companies an opportunity to access local markets before expanding globally and a strong reason to anchor themselves in Canada,” said Gail Garland, President and CEO of OBIO. “With EAHN, OBIO is partnering innovators and health organizations to get innovative technologies, including COVID-19-related technologies, into the health care system and to patients faster than ever before, realizing both the health and economic benefits that health science innovators within our own country can offer.”
EAHN is flexible and evaluates innovations across the health technology spectrum, from medical devices and COVID-19 solutions to digital tools that manage the continuum of care, following patients on their care journeys. EAHN will get these innovative technologies into the health care system faster and disseminated.
Continue reading here